within Pharmacolibrary.Drugs.N_NervousSystem.N02C_AntimigrainePreparations.N02CC01_Sumatriptan;

model Sumatriptan
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.15,
    Cl = 1.9333333333333333e-05,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.0024,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0025,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Sumatriptan</td></tr><tr><td>ATC code:</td><td>N02CC01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2.4</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1160</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Sumatriptan is a selective serotonin (5-HT1B/1D) receptor agonist used primarily for the acute treatment of migraine attacks with or without aura. It is approved for use and is considered effective in aborting migraine headaches.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects following a single oral dose administration.</p><h4>References</h4><ol><li><p>Ohk, B, et al., &amp; Yoo, H (2022). Evaluation of sex differences in the pharmacokinetics of oral sumatriptan in healthy Korean subjects using population pharmacokinetic modeling. <i>Biopharmaceutics &amp; drug disposition</i> 43(1) 23–32. DOI:<a href=\"https://doi.org/10.1002/bdd.2307\">10.1002/bdd.2307</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34923646/\">https://pubmed.ncbi.nlm.nih.gov/34923646</a></p></li><li><p>Fuseau, E, et al., &amp; Ibbotson, T (2002). Clinical pharmacokinetics of intranasal sumatriptan. <i>Clinical pharmacokinetics</i> 41(11) 801–811. DOI:<a href=\"https://doi.org/10.2165/00003088-200241110-00002\">10.2165/00003088-200241110-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12190330/\">https://pubmed.ncbi.nlm.nih.gov/12190330</a></p></li><li><p>Dilone, E, et al., &amp; Fox, AW (2009). Rapid oral transmucosal absorption of sumatriptan, and pharmacodynamics in acute migraine. <i>Headache</i> 49(10) 1445–1453. DOI:<a href=\"https://doi.org/10.1111/j.1526-4610.2009.01475.x\">10.1111/j.1526-4610.2009.01475.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19549162/\">https://pubmed.ncbi.nlm.nih.gov/19549162</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N02CC01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Sumatriptan;
